Clinical trials: Leiomyosarcoma Metastatic
Cancer
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
RATIONALE: Learning about the relationship between platinum levels in the blood and neurotoxicity in patients receiving oxaliplatin may help plan treatment and may help patients live more comfortably.
- Trial name
- NCT00274885
- Testing
- oxaliplatin, management of therapy complications
- Where
- 6 sites in France
- Volunteers
- 58 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 1b, Open Label
A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.
- Conditions
- Phase 1b, Open Label, REC-617, RB1-Negative
- Trial name
- NCT07633756
- Testing
- REC617
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Cancer
Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma
The purpose of this study is to assess the overall response rate (ORR) of persistent, recurrent or metastatic leiomyosarcoma in patients treated with ARQ 501.
- Trial name
- NCT00310518
- Testing
- ARQ 501
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Leiomyosarcoma or Carcinosarcoma
Pazopanib Vs. Pazopanib Plus Gemcitabine
This study is a prospective, randomized, open-label, multicenter phase II trial in order to determine progression-free survival of patients with refractory or relapsed metastatic uterine leiomyosarcomas or other metastatic…
- Trial name
- PazoDoble (NCT02203760)
- Testing
- Pazopanib plus Gemcitabine, Pazopanib
- Where
- 9 sites in Germany
- Volunteers
- 58 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Leiomyosarcoma
Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)
The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in metastatic leiomyosarcoma patients.
- Trial name
- FIBROSARC US (NCT03420014)
- Testing
- Doxorubicin, L19TNF plus doxorubicin
- Where
- 8 sites in United States
- Volunteers
- 114 people
- Sponsor
- Philogen S.p.A.
Leiomyosarcoma, Pleomorphic Liposarcoma
Detection of Circulating Tumor Cells in Patients With Sarcomas
The sarcomas represent 1% of all cancers in adults, 8% in adolescents and young people, and 10% in children. Even though it is a rare cancer, it contributes to a significant loss of years of life in comparison with other types of…
- Conditions
- Leiomyosarcoma, Pleomorphic Liposarcoma, Synovial Sarcoma, Liposarcoma
- Trial name
- CTCS (NCT02983539)
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- AC Camargo Cancer Center
Sarcoma
Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00227669
- Testing
- docetaxel, gemcitabine hydrochloride
- Where
- 32 sites in France
- Volunteers
- 90 people
- Sponsor
- UNICANCER
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Sarcoma
Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Ovarian Cancer, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00025441
- Testing
- dactinomycin, filgrastim, carboplatin
- Where
- 22 sites in France, Ireland and 1 more
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
Cancer
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005860
- Testing
- floxuridine, leucovorin calcium, oxaliplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Leiomyosarcoma
Metastatic Leiomyosarcoma Biomarker Protocol
Leiomyosarcoma (LMS) is one of the most prevalent soft tissue sarcomas (STS) and can occur in various sites including soft tissue, uterus and retroperitoneal large vessels.
- Trial name
- NCT05653388
- Testing
- Plasma Collection
- Where
- 11 sites in United States, Australia
- Volunteers
- 200 people
- Sponsor
- University of Michigan Rogel Cancer Center
Cancer
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003867
- Testing
- capecitabine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
Anal Cancer, Carcinoma of the Appendix
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00654160
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Leiomyosarcoma of Ovary, Soft Tissue Sarcoma
Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
Study is aimed at evaluating the activity of Trabectedin (arm A) in advanced leiomyosarcomas, having Gemcitabine (arm B) as the comparator.
- Trial name
- ISG-ARTICLE (NCT04383119)
- Testing
- Trabectedin, Gemcitabine, No Intervention: Observational Cohort
- Where
- 17 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Italian Sarcoma Group
High Grade Sarcoma, Metastatic Leiomyosarcoma
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
This phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or…
- Conditions
- High Grade Sarcoma, Metastatic Leiomyosarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor, Metastatic Synovial Sarcoma
- Trial name
- NCT02601209
- Testing
- Pazopanib, Pazopanib Hydrochloride, Sapanisertib
- Where
- 460 sites in United States
- Volunteers
- 151 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00030784
- Testing
- ifosfamide, pegylated liposomal doxorubicin hydrochloride
- Where
- 2 sites in Denmark, Germany
- Volunteers
- 28 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Leiomyosarcoma, Liposarcoma
Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin
Two arm, randomized, open-label study, to determine the best time to secondary resistance between responding patients who discontinue treatment and resumed Trabectedin at the time of progression versus patients who continued…
- Conditions
- Leiomyosarcoma, Liposarcoma, Synovial Sarcoma
- Trial name
- TRADITIONS (NCT03773510)
- Testing
- Trabectedin discontinuation, Trabectedin continuation
- Where
- 15 sites in Italy
- Sponsor
- Italian Sarcoma Group
Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
This pilot phase I trial studies how well itacitinib works in treating patients with sarcomas that do not respond to treatment (refractory) and have spread to other parts of the body (advanced/metastatic).
- Conditions
- Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Advanced Myxoid Liposarcoma
- Trial name
- NCT03670069
- Testing
- Itacitinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Fred Hutchinson Cancer Center